SEC Company Response from ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682) (NDRA) — Jan 22, 2020
ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)
Date: Jan. 22, 2020 · CIK: 0001681682 · Accession: 0001654954-20-000666
AI Filing Summary & Sentiment
File numbers found in text: 333-235883
Show Raw Text
CORRESP 1 filename1.htm Blueprint ENDRA Life Sciences Inc. 3600 Green Court, Suite 350 Ann Arbor, MI 48105 January 22, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento Re: ENDRA Life Sciences Inc. Registration Statement on Form S-3 File No. 333-235883 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, registrant ENDRA Life Sciences Inc. hereby respectfully requests that the above-referenced Registration Statement on Form S-3 be declared effective at 5:00 p.m., Eastern Time, on Thursday, January 23, 2020, or as soon thereafter as is practicable. Please direct any questions regarding this request to Mark Busch of K&L Gates LLP ((704) 331-7440; mark.busch@klgates.com). In addition, please notify Mr. Busch when this request for acceleration has been granted. Sincerely, /s/ David Wells David Wells Chief Financial Officer